HLA-DRA

HLA-DRA Full Name

major histocompatibility complex, class II, DR alpha

HLA-DRA Introduction

HLA-DRA encodes the alpha chain of the MHC class II DR molecule, a critical component of antigen presentation in adaptive immunity. This gene plays a central role in presenting extracellularly derived peptides to CD4+ T cells, enabling effective immune surveillance and response. Clinically, HLA-DRA has emerged as a key molecular marker with potential to guide patient management, particularly in contexts where immune recognition is crucial. Its expression reflects not only the capacity of antigen-presenting cells to stimulate T cell responses but also the overall immune status of tissues, offering a mechanistic window into disease progression, immune escape, and treatment responsiveness.

Functionally, HLA-DRA is intimately involved in shaping the immune microenvironment across various tissues. High expression of HLA-DRA enhances antigen presentation, promoting CD4+ T cell activation and downstream adaptive immune responses. Conversely, dysregulation or epigenetic modification of HLA-DRA can impair immune surveillance, allowing tumor cells or pathogens to evade detection. In cancers such as non-small cell lung cancer, cervical cancer, and low-grade glioma, HLA-DRA expression levels correlate with both immune infiltration and clinical outcomes, highlighting its dual role in regulating anti-tumor immunity and serving as a measurable biomarker for prognosis and therapeutic response.

Disease association studies further underscore HLA-DRA's relevance in oncology and immune-mediated disorders. In non-small cell lung cancer, elevated HLA-DRA predicts stronger responses to immune checkpoint inhibitors, reflecting its role in antigen presentation and T cell priming. In cervical cancer, progressive upregulation of HLA-DRA during the transition from normal tissue to carcinoma suggests involvement in tumor progression and potential utility as a biomarker for disease staging. Low-grade glioma research links higher HLA-DRA expression to poorer overall survival, emphasizing its complex relationship with tumor immunity. Additionally, in gastric cancer, epigenetic regulation of HLA-DRA via DNA methylation appears to influence cancer risk, likely by modulating immune surveillance. Collectively, these findings position HLA-DRA as a clinically and biologically significant target for understanding immune interactions, predicting therapy outcomes, and assessing disease risk across multiple pathologies.

Alternate Names for HLA-DRA

HLA-DRA; major histocompatibility complex, class II, DR alpha; MLRW; HLA-DRA1; HLA class II histocompatibility antigen, DR alpha chain; MHC class II antigen DRA; MHC cell surface glycoprotein; histocompatibility antigen HLA-DR alpha;

• 1.Mei J, et al.; HLA class II molecule HLA-DRA identifies immuno-hot tumors and predicts the therapeutic response to anti-PD-1 immunotherapy in NSCLC. BMC Cancer. 2022, 22(1):738.
  2.Balakrishnan CK, et al.; CD74 and HLA-DRA in Cervical Carcinogenesis: Potential Targets for Antitumour Therapy. Medicina (Kaunas). 2022, 58(2):190.